COMPOSITION:

Each film-coated tablet contains Erdafitinib ............4 mg  

INDICATION:  

LuciErda is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) that has

• susceptible FGFR3 or FGFR2 genetic alterations and

• progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.

DOSAGE AND USE:

• Confirm the presence of FGFR genetic alterations in tumor specimens prior to initiation of treatment with LuciErda.

• Recommended initial dosage: 8 mg orally once daily with a dose increase to 9 mg daily if criteria are met.

• Swallow whole with or without food.

STORAGE:

in a dry place and store at 20°C to 25°C.

MANUFACTURED AND MARKETED BY: 

LUCIUS PHARMACEUTICALS(LAO) CO., LTD

No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

WARNING:

Keep medicine out of reach of Children. Do not administer LuciErda during Pregnancy and Lactation.